This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.
1A Strudwick , WJ Mutch , I Dingwall-Fordyce . Parkinson's disease–functional impairment and who helps. Clin Rehabil 1990; 4: 213–16.
2Zhen-Xin Zhang , GC Roman . Worldwide occurrence of Parkinson's disease: an updated review. Neuroepidemiology 1993; 12: 195–208.
3WJ Mutch , I Dingwall-Fordyce , AW Downie , JG Paterson , SK Roy . Parkinson's disease in a Scottish city. Br Med J 1986a; 292: 534–36.
4R D'Alessandro , G Gamberini , F Graniere , G Benassi , S Naccarato , D Manzaroli . Prevalence of Parkinson's disease in the Republic of San Marino. Neurology 1987; 37: 1679–82.
6NE Bharucha , EP Bharucha , AE Bharucha , AV Bhise , BS Schoenberg . Prevalence of Parkinson's disease in the Parsi Community in Bombay, India. Arch Neurol 1988; 45: 1321–23.
7AH Rajput , KP Offord , CM Beard , LT Kurland . Epidemiology of Parkinsonism: incidence, classification and mortality. Ann Neurol 1984; 16: 278–82.
8KP Ebmeier , SA Calder , JR Crawford , L Stewart , JAO Besson , WJ Mutch . Parkinson's disease in Aberdeen: survival after 3.5 years. Acta Neurol Scand 1990; 81: 294–99.
10GA Ricaurte , I Irwin , LS Forno , LE Delanney , EB Langston , JW Langston . Ageing and MPTP-induced degeneration of dopaminergic neurones in the substantia nigra. Brain Res 1987; 403: 43–51.
11J De Pedro . Tracers for paralysis agitans in epidemiological research v. prevalence of the disease in Swedish counties. Neuroepidemiology 1986; 5: 207–19.
12BS Schoenberg . Clinical neuroepidemiology in developing countries. Neuroepidemiology 1982; 1: 137–42.
13WJ Mutch , WC Smith , RF Scott . A screening and alerting questionnaire for Parkinsonism. Neuroepidemiology 1991; 10: 150–56.
14RE Laporte . Assessing the human condition: capture-recapture techniques. Br Med J 1994; 308: 5–6.
16CD Ward , RC Duvoisin , SE Ince , JD Nutt , R Eldridge , DB Calne . Parkinson's disease in 65 pairs of twins and in a set of quadruplets. Neurology 1983; 33: 815–24.
17WG Johnson , Hodges, R Duvoisin . Twin studies and the genetics of Parkinson's disease-a reappraisal. Mov Disord 1990; 5: 187–94.
18LI Golbe , G Do Iorio , V Bonavita Autosomal dominant Parkinson's disease. Ann Neurol 1990; 27: 276–82.
19A Barbeau , M Roy . Familial subsets in idiopathic Parkinson's disease. Can J Neurol Sci 1984; 11: 144–50.
20PA Ballard , JW Tetrud , JW Langston . Permanent human Parkinsonism due to MPTP. Neurology 1985; 35: 949–56.
23SM Aquilonius , P Hartvig . A Swedish county with unexpectedly high utilisation of anti-Parkinsonian drugs. Acta Neurol Scand 1986; 74: 379–82.
24JW Langston , I Irwin . Pyridine toxins. In: DB Calne ed. Drugs for the treatment of Parkinson's disease. Handbook Exp Pharm 88. Berlin: Springer-Verlag, 1989: 205.
25KP Ebmeier , WJ Mutch , SA Calder , JR Crawford , L Stewart , JAO Besson . Does idiopathic Parkinsonism in Aberdeen follow intra-uterine influenza? J Neurol Neurosurg Psychiatry 1989; 52: 911–13.
26KM Semchuk , EJ Love , RG Lee . Parkinson's disease and exposure to agricultural work and pesticide chemicals. Neurology 1992; 42: 1328–35.
27JP Hubble , BS Cao , RES Hassanein . JS Neuberger , WC Koller . Rick factors for Parkinson's disease. Neurology 1993; 43: 1693–97.
28PL McGeer , E McGeer , JS Suzuki . Ageing and extra-pyramidal function. Arch Neurol 1977; 34: 33–35.
30WRG Gibb , AJ Lees . The progression of idiopathic Parkinson's disease is not explained by age-related changes. Clinical and pathological comparisons with post-encephalitic Parkinsonian syndrome. Acta Neuropathol 1987; 73: 195–201.
31B Halliwell . Oxidants and the central nervous system: some fundamental questions. Acta Neurol Scand 1989; 80 (suppl 126): 23–33.
32RR Ramsay , JI Salach , J Dadgar , TP Singer . Inhibition of mitochondrial NADH dehydrogenase by pyridine derivatives and its possible relation to experimental and idiopathic Parkinsonism. Biochem Biophys Res Commun 1986; 135: 269–75.
33VM Mann , JM Cooper , D Krige , SE Daniel , AHV Schapira , CD Marsden . Brain, skeletal muscle and platelet mitochondrial function in Parkinson's disease. Brain 1992; 115: 333–42.
34D Krige , MT Carroll , JM Cooper Platelet mitochondrial function in Parkinson's disease. Ann Neurol 1992; 32: 782–88.
35CAD Smith , AC Gough , PN Leigh Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet 1992; 339: 1375–77.
36M Armstrong , AK Daly , S Cholerton , DN Bateman , JR Idle . Mutant debrisoquine hydroxylation genes in Parkinson's disease. Lancet 1992; 339: 1017–18.
37WD Parker , SJ Boyson , JK Parks . Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol 1989; 26: 719–23.
39DT Dexter , FR Wells , AJ Lees Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem 1989; 52: 1830–36.
40DT Dexter , C Carter , FR Wells Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 1989; 52: 381–89.
42CW Olanow . A scientific rationale for protective therapy in Parkinson's disease. J Neural Transm 1993; 91: 161–80.
44P Riederer , S Wuketich . Time course of nigrostriatal degeneration in Parkinson's disease. J Neural Transm 1976; 38: 227–301.
45S Fahn , G Cohen . The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol 1992; 32: 804–12.
46DB Calne . The free radical hypothesis in idiopathic Parkinsonism: evidence against it. Ann Neurol 1992; 32: 799–803.
48WRG Gibb , AJ Lees . A comparison of clinical and pathological features of young-and old-onset Parkinson's disease. Neurology 1988; 38: 1402–1406.
50CJ Turnbull , JA Aitken . Diagnosis and management of ‘Parkinsonism’ in the elderly. Age Aging 1983; 12: 309–16.
51WJ Zetusky , J Jankovic , FJ Pirozzolo . The heterogeneity of Parkinson's disease: clinical and prognostic implications. Neurology 1985; 35: 522–26.
52M Hietanen , H Teravainen . The effect of age of disease onset on neuropsychological performance in Parkinson's disease. J Neurol Neurosurg Psychiatry 1988; 51: 244–49.
54KP Ebmeier , SA Calder , JR Crawford , L Stewart , JAO Besson , WJ Mutch . Clinical features predicting dementia in idiopathic Parkinson's disease: a follow–up study. Neurology 1990; 40: 1222–24.
58S Gauthier , L Gauthier . Current status of levodopa therapy in idiopathic Parkinson's disease. Can J Neurol Sci 1987; 14: 452–54.
59SG Diamond , CH Markham , MM Hoehn , FH McDowell , MD Muenter . Effect of age at onset on progression and mortality in Parkinson's disease. Neurology 1989; 39: 1187–90.
60JA Wilson , RG Smith . The prevalence and aetiology of long-term L-dopa side-effects in elderly Parkinsonian patients. Age Ageing 1989; 18: 11–16.
62CG Goetz , CM Tanner , GT Stebbins , AS Buchman . Risk factors for progression in Parkinson's disease. Neurology 1988; 38: 1841–44.
63JM Cederbaum . Clinical pharmacokinetics of anti-Parkinsonian drugs. Clin Pharmacokinet 1987; 13: 141–78.
64WH Poewe , AJ Lees , GM Stern . Treatment of motor fluctuations in Parkinson's disease with an oral sustained release preparation of L-dopa: clinical and pharmacokinetic observations. Clin Neuropharmacol 1986; 9: 430–39.
66R Pahwa , RN Busenbark , SJ Huber Clinical experience with controlled-release carbidopa/levodopa in Parkinson's disease. Neurology 1993; 43: 677–81.
68JG Nutt , WR Woodward , JH Carter , TL Trotman . Influence of fluctuations of plasma large neutral amino acids with normal diets on the clinical response to levodopa. J Neurol Neurosurg Psychiatry 1989; 52: 481–87.
69A Laihinen , JO Rinne , UK Rinne , M Haaparanta , U Ruotsalainen . F18-6-Fluorodopa PET scanning in Parkinson's disease after selective COMT inhibition with nitecapone (RO-462). Neurology 1992; 42: 199–203.
70SA Factor , D Brown . Clozapine prevents recurrence of psychosis in Parkinson's disease. Mov Disord 1992; 7: 125–31.
73UK Rinne . Dopamine agonist treatment in early Parkinson's disease. In: H Przuntek , P Riederer eds. Early diagnosis and preventive therapy in Parkinson's disease. Wien: Springer-Verlag, 1989: 343.
74AJ Lees , J Frankel , V Eatough , GM Stern . New approaches in the use of selegiline for the treatment of Parkinson's disease. Acta Neurol Scand 1989; 80 (suppl 126): 139–45.
77GL Zornberg . Severe adverse interaction between pethidine and selegiline. Lancet 1991; 337: 246.
78W Birkmayer , J Knoll , P Riederer , MBH Youdim , V Hars , J Marlon . Increased life expectancy resulting from addition of L-Deprenyl to Madopar treatment in Parkinson's disease: a long-term study. J Neural Transm 1985; 64: 113–27.
79JW Tetrud , WJ Langston . The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science 1989; 245: 519–22.
80The Parkinson study group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989; 321: 1364–71.
81The Parkinson study group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993; 328: 176–83.
82Parkinson's Disease Research Group of the United Kingdom. Comparisons of therapeutic effects of levodopa, levodopa and selegiline and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. Br Med J 1993; 307: 469–72.
83AJ Hughes , S Bishop , B Kleedorfer Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years. Mov Disord 1993; 8: 165–70.
85WJ Weiner , SA Factor , JR Sanchez-Ramos Early combination (bromocriptine and levodopa) does not prevent motor fluctuations in Parkinson's disease. Neurology 1993; 43: 21–27.
88O Lindvall , H Widner , P Rehncrona Transplantation of fetal dopaminergic neurons in Parkinson's disease: one year clinical and neuropsychological observations in two patients with putamenal implants. Ann Neurol 1992; 31: 155–65.
90CR Freed , RE Breeze , NL Rosenberg Survival of implanted fetal dopamine cells and neurological improvement 12 to 46 months after transplantation for Parkinson's disease. N Engl J Med 1992; 327: 1549–55.
91JS Schneider , A Pope , K Simpson , J Taggert , MC Smith , L de Stephano . Recovery from experimental Parkinsonism in primates with GMI ganglioside treatment. Science 1992; 256: 843–46.
92CG Goetz , MR Delong , RD Penn , RAE Bakay . Neurosurgical horizons in Parkinson's disease. Neurology 1993; 43: 1–7.
94LV Laitinen , AT Bergenheim , MI Hariz . Leksell's postero-ventral pallidotomy in the treatment of Parkinson's disease. J Neurosurg 1992; 76: 53–61.
95AL Benabid , P Pollak , C Gervason Long-term suppression of tremor by chronic stimulation of the ventral intermediate thalamic nucleus. Lancet 1991; 337: 403–406.